Last updated: 6 February 2024 at 4:55pm EST

Asset Management, Lp Cormor... Net Worth




The estimated Net Worth of Asset Management, Lp Cormor... is at least $77.7 million dollars as of 2 February 2024. Asset Cormor owns over 750,000 units of Corbus Pharmaceuticals Inc stock worth over $77,747,250 and over the last few years Asset sold CRBP stock worth over $0.

Asset Cormor CRBP stock SEC Form 4 insiders trading

Asset has made over 2 trades of the Corbus Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Asset bought 750,000 units of CRBP stock worth $14,250,000 on 2 February 2024.

The largest trade Asset's ever made was buying 750,000 units of Corbus Pharmaceuticals Inc stock on 2 February 2024 worth over $14,250,000. On average, Asset trades about 516,316 units every 4 days since 2024. As of 2 February 2024 Asset still owns at least 1,475,000 units of Corbus Pharmaceuticals Inc stock.

You can see the complete history of Asset Cormor stock trades at the bottom of the page.



Insiders trading at Corbus Pharmaceuticals Inc

Over the last 10 years, insiders at Corbus Pharmaceuticals Inc have traded over $3,643,182 worth of Corbus Pharmaceuticals Inc stock and bought 2,676,074 units worth $50,292,165 . The most active insiders traders include Asset Management, Lp Chen B..., Asset Management, Lp Cormor... et Sean F. Moran. On average, Corbus Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $1,059,576. The most recent stock trade was executed by Sean F. Moran on 14 June 2024, trading 18,043 units of CRBP stock currently worth $233,837.



What does Corbus Pharmaceuticals Inc do?

corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.



What does Corbus Pharmaceuticals Inc's logo look like?

Corbus Pharmaceuticals Holdings Inc logo

Complete history of Asset Cormor stock trades at Corbus Pharmaceuticals Inc

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
2 Feb 2024 Asset Management, Lp Cormor...
Acheter 750,000 $19.00 $14,250,000
2 Feb 2024
1,475,000
26 Jan 2024 Asset Management, Lp Cormor...
Acheter 282,632 $32.24 $9,112,056
26 Jan 2024
725,000


Corbus Pharmaceuticals Inc executives and stock owners

Corbus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: